Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

NOVAVAX INC (NVAX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News & Media Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe October 29, 2026 · The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden

Event · Contract
Role
customer
Counterparty
Sanofi
Value
$125 million
Scope
Nuvaxovid

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Oct 29, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NVAX
Bullish
high confidence
Mentioned
$NVAX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NVAXBullishHigh
01

Why it matters

The $125 M payment provides immediate liquidity and validates the partnership, likely supporting NVAX's share price in the short term.

02

Market read

First disclosure of a sizable milestone payment that could boost NVAX's near‑term valuation.

03

What to watch

Potential delays in technology transfer and manufacturing could postpone further payments and royalties.

Relevance 8/10Novelty 8/10Timing: today

Background

Novavax's partnership with Sanofi includes multiple future milestones and royalty streams tied to a combined influenza‑COVID‑19 vaccine.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax received a $125 million milestone payment as Sanofi initiated the Phase 3 trial of their influenza‑COVID‑19 combination vaccine.

Expected impact

likely upside as the market prices in the milestone payment and future royalty potential

Evidence & confidence

Milestone payments are material cash events; the $125 M amount is sizable for NVAX and signals continued partnership revenue.

Market effects

strengthens the vaccine partnership sector and may boost other biotech firms with similar collaboration models

positive for US biotech equities as the milestone underscores US‑Europe vaccine collaborations

reinforces confidence in combined flu‑COVID vaccine development worldwide

Counterpoint

The milestone may be a one‑off cash event; long‑term revenue depends on future trial success and regulatory approval.

Key entities

  • Novavax Inc.

    Biotech firm receiving the milestone payment.

  • Sanofi

    Partner conducting the Phase 3 trial.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.